New drug cocktail aims to tackle tough lymphoma
NCT ID NCT07570017
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called rocbrutinib combined with standard chemotherapy (R-GemOx) in 42 people with a type of lymphoma (DLBCL) that has returned or not responded to treatment. The main goals are to find a safe dose and see if the combination shrinks tumors. It is a small, early study focused on safety first.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rocbrutinib (LP-168) combined with rituximab, gemcitabine, and oxaliplatin (R-GemOx)
- What this could lead to
- If successful, this could point toward a new treatment option for people with a hard-to-treat type of lymphoma that has come back or not responded to prior therapy.
- What could go wrong
- This is a very early (Phase Ib) trial with only 42 participants, so it is primarily testing safety and dosing. The combination may not prove effective or could cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510050, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill boost Chemotherapy's punch against lymphoma?
- Real-World data may reveal how well tafasitamab fights Hard-to-Treat lymphoma
- Off-the-Shelf immune cells take on tough lymphoma
- New cocktail aims to tame aggressive lymphoma in the very elderly
- New hope for aggressive lymphoma: triple-drug combo enters human trials
- New drug cocktail targets Hard-to-Treat brain cancer